The gold standard for sensitive screening for genes that can predispose a patient to particular cancer types, such as pathogenic variants in GNAS, was PCR amplification, followed by sequencing, e.g., Sanger sequencing (also known as dideoxy chain termination method) of the amplified product [30–34]. This evidence concerns the gene GNAS and cancer.